Differential antiatherogenic effects of PPARalpha versus PPARgamma agonists: should we be surprised?
Camejo
Germán
G
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000503:physiopathology*; D002995:Clofibric Acid / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D047493:PPAR alpha / Q000819:agonists* / Q000502:physiology; D047495:PPAR gamma / Q000819:agonists* / Q000502:physiology
D007004:Hypoglycemic Agents; D047493:PPAR alpha; D047495:PPAR gamma; D002995:Clofibric Acid